Leaning on its in-house life sciences expertise GV has backed another biotech startup in the UK, co-leading a £20 million ($27.1M) Series A in Oxford University spinout Vaccitech, which is developing a universal flu vaccine. Read More
Permalink — http://feedproxy.google.com/~r/Techcrunch/~3/o-LFV1c_bLk/
URL of source article.
Date — January 15, 2018 3:20 pm
Publish date of source article.
Source — http://feeds.feedburner.com/TechCrunch
URL of RSS feed.
Advertisements
